SOPHiA GENETICS SA (SOPH) AI Stock Analysis

SOPHiA GENETICS SA functions as a healthcare technology company specializing in advanced data analysis solutions. At the core of its offerings is the SOPHiA DDM platform, a cloud-based software-as-a-service tool designed to analyze extensive datasets and diagnostic modalities. This platform enables hospitals, laboratories, and biopharma entities to derive actionable insights from complex data. It facilitates the interpretation of multimodal datasets by integrating genomic, radiomic, and clinical data to enhance precision medicine initiatives. Founded in 2011 and headquartered in Saint-Sulpice, Switzerland, the company employs 415 people and utilizes artificial intelligence to advance patient care and therapeutic development.

Revenue expanded from $40.5M in FY2021 to $47.6M in FY2022, $62.4M in FY2023, $65.2M in FY2024, and reached $77.3M in FY2025, reflecting a 5-year revenue CAGR of 22.2%. Revenue growth in FY2025 was 18.6%, while gross margin stood at 61.9%. Operating margins remained negative across all reported periods, finishing at -91.8% in FY2025 alongside a net income of -$79.0M. For the trailing twelve months ending June 30, 2026, revenue totaled $86.2M with quarterly revenue growth of 27.2% year-over-year. The trailing twelve-month operating margin was -86.0%, profit margin was -93.9%, and diluted earnings per share stood at -$1.16.

As of June 30, 2026, SOPHiA GENETICS held $107.7M in cash and short-term investments against total debt of $61.8M, yielding net cash of $45.8M. Total assets were $198.4M and shareholders' equity was $83.1M. The company reported a current ratio of 2.69 and a debt-to-equity ratio of 0.74. In FY2025, operating cash flow was -$38.0M and free cash flow was -$38.6M. Capital expenditures in FY2025 were $574,000, while the 5-year share count change was 23.9%.

At a last close price of $6.73, SOPHiA GENETICS had a market capitalization of $572.9M and an enterprise value of $646.7M. The stock trades at a price-to-sales multiple of 6.6x and an EV to revenue multiple of 7.5x, above the median of its US-listed Healthcare peers of 4.1x for price-to-sales. Over the past year, the stock returned 51.6%, outperforming the S&P 500 return of 16.8%. Over a 5-year period, however, the shares declined 58.2%, trailing the S&P 500 return of 83.0%.

All 5 analysts tracking SOPHiA GENETICS rate the stock a StrongBuy, with 0 Buy, 0 Hold, 0 Sell, and 0 StrongSell ratings. The mean price target is $9.75, which stands 44.9% above the last close price of $6.73. For the current fiscal year ending December 31, 2026, analysts estimate revenue of $95.2M and an EPS of -$0.85. The company beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 3, 2026.

This page is an AI-written research summary of SOPHiA GENETICS SA (SOPH). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SOPH income statement, SOPH balance sheet, SOPH key metrics, SOPH analyst forecast, SOPH chart. See the SOPH stock overview for the latest quote and news.